236 studies on GIP-R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
Tirzepatide's real-world efficacy in improving sleep-disordered breathing offers a significant practical takeaway for clinicians and individuals managing obesity and type 2 diabetes. Beyond weight loss and glycemic co…
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentat…
Understanding patient and provider preferences for tirzepatide and CPAP in obesity and OSA is critical for optimizing treatment strategies and improving adherence. If patients show a strong preference for a pharmacolo…
This finding offers a promising new therapeutic avenue for managing Fabry disease, particularly for patients experiencing residual proteinuria despite current standard-of-care treatments. DUAL GIP/GLP-1Ra could signif…
Updated 2026 guidelines for obesity and type 2 diabetes mellitus emphasize the crucial role of modern GLP-1 analogues and tirzepatide in comprehensive management.
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
This real-world study provides crucial validation that tirzepatide effectively promotes meaningful weight loss in both Type 2 Diabetes and non-diabetic obese adults, reinforcing its broad utility. The observed glycemi…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
This research provides compelling evidence for a novel mechanism by which Tirzepatide protects against cisplatin-induced AKI, specifically through its ability to restore NAD+ levels and enhance mitochondrial quality c…
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
This trial is crucial because it seeks to provide a much-needed treatment option for obesity in individuals with Type 1 Diabetes, a population with limited pharmacological interventions. A successful outcome could sig…
The potential for a therapeutic strategy that not only achieves significant weight loss but also preserves crucial muscle mass and bone health would be a major advancement in obesity management. Current weight loss ap…
This comparative review is crucial for clinicians and patients in making informed treatment decisions, highlighting the distinct strengths of each medication. The findings underscore Tirzepatide's potent efficacy in w…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
This comprehensive "Evidence Map" highlights the transformative potential of incretin-based anti-obesity medications as a crucial therapeutic strategy for women suffering from PCOS and obesity. By consolidating existi…
This case highlights the critical importance of vigilant monitoring of thyroid function in post-thyroidectomy patients initiating tirzepatide or similar incretin-based medications. The significant weight loss and pote…
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
This study provides important reassurance regarding the cardiovascular safety profile of tirzepatide in a high-risk population. Given tirzepatide's superior efficacy in glycemic control and weight reduction, demonstra…
This study provides reassuring short-term data regarding tirzepatide and calcitonin levels, suggesting that while a slight increase may occur, it generally remains within a safe range for adults with obesity. This fin…
This comprehensive review underscores the critical role of the gut microbiome as a mediator of GLP-1 therapy effects on liver health, particularly in patients with Type 2 Diabetes Mellitus. Understanding these mechani…
The findings from this study are highly significant for patients managing type 2 diabetes and obesity with Tirzepatide. Knowing that injection site (upper arm, thigh, or abdomen) does not significantly impact drug abs…
This case report is significant as it highlights a previously unreported dermatological adverse event associated with tirzepatide use. Clinicians prescribing tirzepatide should be aware of SDRIFE as a potential, albei…
This comprehensive analysis strengthens the evidence for Tirzepatide's potential as a multi-organ protective agent, extending its utility beyond metabolic control. The findings suggest that Tirzepatide could be a valu…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
This finding suggests that initiating Tirzepatide in patients with type 2 diabetes who are new to GLP-1 receptor agonists may offer a distinct and superior advantage in improving liver health, specifically regarding f…
This research introduces a groundbreaking approach to treating obesity and diabetes by simultaneously targeting multiple metabolic pathways. By combining GLP-1R, GIPR, and PPARα/γ/δ agonism, this strategy could offer …
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
This study provides crucial evidence suggesting that Tirzepatide offers superior weight loss efficacy compared to oral semaglutide, which can significantly inform clinical decision-making for managing overweight and o…
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores th…
This review highlights the broad therapeutic potential of GLP-1RAs and dual GIP/GLP-1RAs, suggesting they could become cornerstone treatments for a multitude of conditions beyond their current approvals. The identifie…
Understanding the direct haemodynamic mechanisms of semaglutide and tirzepatide is crucial for optimizing their use in patients with cardiovascular diseases. This research could reveal novel pathways through which the…
This summary from an ICER council is crucial because it provides an independent, evidence-based assessment of the clinical and economic value of two highly effective anti-obesity medications. Such reviews are instrume…
This Phase 2 trial is crucial as it explores a novel combination therapy that could significantly advance the treatment landscape for obesity and Type 2 Diabetes. If successful, combining LY3841136 with Tirzepatide co…
This study addresses a critical unmet need for patients with psoriatic arthritis who also struggle with obesity, a common comorbidity that complicates disease management and often reduces the effectiveness of existing…
This research underscores a critical challenge in obesity management, suggesting that the benefits of Tirzepatide on weight loss may necessitate continuous or long-term administration to prevent relapse. The rapid wei…
This study provides compelling real-world evidence that low-to-moderate doses of Tirzepatide are highly effective and well-tolerated for weight management in adults with obesity in routine clinical practice. The obser…
This review underscores the critical role of tailored dietary strategies in maximizing the therapeutic benefits of GLP-1 and dual GIP/GLP-1 receptor agonists. It suggests that integrating specific nutritional guidance…
This study provides crucial real-world evidence that Tirzepatide not only induces substantial weight loss but also favorably alters body composition by preserving lean mass and significantly improving muscle function …
This comprehensive review provides a critical, evidence-based framework for clinicians managing Type 2 Diabetes, moving beyond a glucose-centric approach. It underscores the importance of personalized medicine, where …
This comprehensive real-world data provides crucial insights for clinicians and patients navigating treatment options for Type 2 Diabetes and obesity. The findings underscore Tirzepatide's potential for greater metabo…